Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 1, 2000, Pages 85-93

  Johnson, Elizabeth M ^a   Oakley, Karen L ^b,d   Radford, Sarah A ^a,e   Moore, Caroline B ^b   Warn, Peter ^b   Warnock, David W ^a,f   Denning, David W ^b,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^d HEALTH AND SAFETY LABORATORY   (United Kingdom)

^e St Martins Hospital   (United Kingdom)

^f NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; CONTROLLED STUDY; DRUG EFFICACY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; SURVIVAL TIME;

EID: 0033978008     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.1.85     Document Type: Article

References (38)

1. Groll, A. H., Shah, P. M., Mentzel, C., Schneider, M., Just-Neubling, G., Huebling, G. et al. (1996). Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. Journal of Infection 33, 23-32.
2. Denning, D. W. (1998). Invasive aspergillosis. Clinical Infectious Diseases 26, 781-805.
3. Kelmenson, V. A. (1959). Treatment of pulmonary aspergillosis. Diseases of the Chest 36, 442-3.
4. Warnock, D. W. (1991). Amphotericin B: an introduction. Journal of Antimicrobial Chemotherapy 28, Suppl B, 27-38.
5. Oppenheim, B. A., Herbrecht, R. & Kusne, S. (1995). The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clinical Infectious Diseases 21, 1145-53.
6. Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, D., Catovsky, C. R. et al. (1997). A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology 98, 711-8.
7. Walsh, T. J., Hiemenz, J. W. & Seibel, N. L. (1998). Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clinical Infectious Diseases 26, 1383-96.
8. Denning, D. W. (1996). Therapeutic outcome of invasive aspergillosis. Clinical Infectious Diseases 23, 608-15.
9. Bowden, R., Chandraseekar, P., White, M., van Burik, J.-A. & Wingard, J. (1998). A double-blind, randomized controlled trial of Amphocil (ABCD) vs. amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients. International Immunocompromised Host Society Meeting, Davos, Switzerland, 1998. Abstract 91.
10. Denning, D. W., Hanson, L. H., Perlman, A. M. & Stevens, D. A. (1992). In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagnostic Microbiology and Infectious Diseases 15, 21-34.
11. Yamada, H., Kohono, S., Maesaki, S., Koga, H., Kaku, M., Hara, K. et al. (1993). Rapid and highly reproducible method for antifungal susceptibility testing of Aspergillus species. Journal of Clinical Microbiology 4, 1009-12.
12. Espinel-Ingroff, A., Dawson, K., Pfaller, M., Anaissie, E., Breslin, B., Dixon, D. et al. (1995). Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrobial Agents and Chemotherapy 39, 314-9.
13. Espinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N. X., Cooper, C., Fothergill, A. et al. (1997). Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. Journal of Clinical Microbiology 35, 139-43.
14. Lass-Florl, C., Kofler, G., Kropshofer, G., Hermans, J., Kreczy, A., Dierich, M. P. et al. (1998). In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. Journal of Antimicrobial Chemotherapy 42, 497-502.
15. Denning, D. W., Radford, S. A., Oakle, K., Hall, L., Johnson, E. M., Warnock, D. W. et al. (1997). Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome for Aspergillus fumigatus infection. Journal of Antimicrobial Chemotherapy 40, 401-14.
16. Carlson, G. L., Birch, M., Mughal, M. M. & Denning, D. W. (1996). Aspergillus wound infection following laparostomy. Journal of Infection 33, 119-21.
17. Denning, D. W., Hall, L., Jackson, M. & Hollis, S. (1995). Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Antimicrobial Agents and Chemotherapy 39, 1809-14.
18. Stiller, R. L., Bennett, J. E., Scholer, H. J., Wall, M., Polak, A., Stevens, D. A. et al. (1983). Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. Journal of Infectious Diseases 6, 1070-7.
19. Polak, A., Odds, F. C., Ludin, E. & Scholer, H. J. (1985). Correlation of susceptibility test results in vitro with response in vivo: ketoconazole therapy in a systemic candidiasis model. Chemotherapy 5, 395-404.
20. Anaissie, E. J., Karyotakis, N. C., Hachem, R., Dignani, M. C., Rex, J. H., Paetznik, V. et al. (1994). Correlation between in vitro and in vivo activity of antifungal agents against Candida species. Journal of Infectious Diseases 170, 384-9.
21. Ghannoum, M. A., Rex, J. H. & Galgiani, J. N. (1996). Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. Journal of Clinical Microbiology 3, 489-95.
22. Wanger, A., Mills, K., Nelson, P. W. & Rex, J. H. (1995). Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrobial Agents and Chemotherapy. 39, 2520-2.
23. Velez, J. D., Allendorfer, R., Luther, M., Rinaldi, M. G. & Graybill, J. R. (1993). Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. Journal of Infectious Diseases 168, 508-10.
24. Witt, M. D., Lewis, R. J., Larsen, R. A., Milefchik, E. N., Leal, M. A. E., Haubrich, R. H. et al. (1996). Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clinical Infectious Diseases 22, 322-8.
25. Troillet, N., Durussel, C., Bille, J., Glauser, M. P. & Chave, J. P. (1993). Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. European Journal of Clinical Microbiology and Infectious Diseases 12, 911-5.
26. Baily, G. G., Perry, F. M., Denning, D. W. & Mandai, B. K. (1994). Management of candidiasis after failure of fluconazole in an HIV cohort. AIDS 8, 787-92.
27. Rühnke, M., Eigler, A., Engelmann, E., Geiseler, B. & Trautmann, M. (1994). Correlation between antifungal susceptibility testing of Candida strains from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22, 132-6.
28. Phillips, P., Zemcov, J., Mahmood, W., Montaner, J. S. G., Craib, K., Clarke, A. M. et al. (1996). Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS. AIDS 10, 1369-76.
29. Rodriguez-Tudela, J.-L., Martinez-Suarez, J. V., Dronda, F., Laguna, F., Chaves, F., Valencia, E. et al. (1995). Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. Journal of Antimicrobial Chemotherapy 35, 793-804.
30. Powderly, W. G., Kobayashi, G. S., Herzig, G. P. & Medoff, G. (1988). Amphotericin B-resistant yeast infection in severely immunocompromised patients. American Journal of Medicine 84, 826-32.
31. O'Day, D. M., Ray, W. A., Robinson, R. D., Head, S. & Williams, T. E. (1991). Differences in response in vivo to amphotericin B among Candida albicans strains. Investigative Ophthalmology and Visual Science 32, 1569-72.
32. Dubé, M. P., Heseltine, P. N. R., Rinaldi, M. G., Evans, S. & Zawacki, B. (1994). Fungemia and colonization with nystatin-resistant Candida rugosa in a bum unit. Clinical Infectious Diseases 18, 77-82.
33. Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W. & Webb, C. D. (1995). Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy 39, 40-4.
34. Vanden Bossche, H., Warnock, D. W., Dupont, B., Kerridge, D., Sen Gupta, S., Improvisi, L., et al. (1994). Mechanisms and clinical impact of antifungal drug resistance. Journal of Medical and Veterinary Mycology 32, Suppl 1, 189-202.
35. Manavathu, E. K., Alangaden, G. J. & Chandrasekar, P. H. (1998). In vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy 41, 615-9.
36. National Committee for Clinical Laboratory Standards. (1998). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-forming Filamentous Fungi: Proposed Standard. NCCLS Document M38-P. NCCLS, Wayne, PA.
37. Denning, D. W. & Stevens, D. A. (1990). Antifungal and surgical treatment of invasive aspergillosis: review of 2, 121 published cases. Reviews of Infectious Diseases 12, 1147-201.
38. Ellis, M., Spence, D., de Pauw, B., Meunier, F., Marinus, A., Collette, L. et al. (1998). An EORTC international multicenter randomised trial (EORTC Number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clinical Infectious Diseases 27, 1406-12.